Prelude Capital Management’s VYNE Therapeutics VYNE Stock Holding History

Prelude Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-64,584	Closed	-$107K	–	1409
2025 Q2	$107K	Sell	64,584 -76,918	-54%	-$100K	0.01%	910
2025 Q1	$224K	Buy	141,502 +82,102	+138%	+$202K	0.02%	870
2024 Q4	$199K	Sell	59,400 -5,747	-9%	-$15K	0.01%	999
2024 Q3	$122K	Buy	65,147 +113	+0.2%	+$214	0.01%	1138
2024 Q2	$128K	Sell	65,034 -29,566	-31%	-$73.7K	0.01%	1074
2024 Q1	$290K	Sell	94,600 -23,500	-20%	-$50.6K	0.02%	910
2023 Q4	$275K	Buy	+118,100	New	+$368K	0.02%	774
2018 Q4	–	Sell	-1	Closed	-$1K	–	2194
2018 Q3	$1K	Sell	1 -27	-96%	-$16.7K	﹤0.01%	1688
2018 Q2	$16K	Buy	+28	New	+$21.8K	﹤0.01%	1395

Other funds holding VYNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Prelude Capital Management's VYNE Position: Q3 2025 in Review

Prelude Capital Management sold out of VYNE Therapeutics (VYNE) in Q3 2025, closing a stake of 64,584 shares — an estimated $107K sold.

Prelude Capital Management first reported a position in VYNE in Q2 2018 and held it in 9 quarters. The position peaked at $290K in Q1 2024. 36 funds tracked by Wall St. Rank hold VYNE as of Q3 2025.

Prelude Capital Management reported no remaining VYNE Therapeutics position as of Q3 2025 after selling out during the quarter.
Prelude Capital Management sold 64,584 VYNE Therapeutics shares in Q3 2025, an estimated $107K.
Prelude Capital Management first reported a position in VYNE Therapeutics in Q2 2018 and held it in 9 quarters.
Prelude Capital Management's VYNE Therapeutics position peaked at $290K in Q1 2024.
36 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.